"We are specifying our full-year outlook for 2022 within the range projected so far, but the global political and economic uncertainties remain high," said Chief Executive Joachim Kreuzburg. Orders were below expectations, analysts at JP Morgan said, adding that was "unlikely to reduce lingering concerns over the outlook for 2023". Analysts on average expect 4.7 billion euros in sales next year, a year-on-year gain of about 12%, according to Refinitiv data. Sartorius has projected roughly 10% annual sales growth through 2025, or about 14% when excluding the expected drop in business related to the coronavirus as drugmakers embrace new high-tech methods such as mRNA, cell therapies and more complex therapeutic proteins. Underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 21.4% to 1.05 billion euros in the first nine months, broadly in line with market expectations.

---